US 7,756,583 B2Grant

Methods and apparatus for intravascularly-induced neuromodulation

Issue Date:2010-07-13

•19 Claims

•7 Drawing Sheets

Abstract

Methods and apparatus are provided for intravascularly-induced neuromodulation using a pulsed electric field, e.g., to effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, changes in cytokine upregulation, etc., in target neural fibers. In some embodiments, the intravascular PEF system comprises a catheter having a pair of bipolar electrodes for delivering the PEF, with a first electrode positioned on a first side of an impedance-altering element and a second electrode positioned on an opposing side of the impedance-altering element. A length of the electrodes, as well as a separation distance between the first and second electrodes, may be specified such that, with the impedance-altering element deployed in a manner that locally increases impedance within a patient's vessel, e.g., with the impedance-altering element deployed into contact with the vessel wall at a treatment site within the patient's vasculature, a magnitude of applied voltage delivered across the bipolar electrodes necessary to achieve desired neuromodulation is reduced relative to an intravascular PEF system having similarly spaced electrodes but no (or an undeployed) impedance-altering element. In a preferred embodiment, the impedance-altering element comprises an inflatable balloon configured to locally increase impedance within a patient's vasculature. The methods and apparatus of the present invention may be used to modulate a neural fiber that contributes to renal function.

Metadata

Assignee

Ardian, Inc.

Inventors

Denise Demarais
Nicolas Zadno
Benjamin J. Clark
Erik Thai

Application Information

Application Number:US 11/266,993

Filing Date:2005-11-04

Priority Date:2002-04-08

Art Unit:3766

Classifications

IPC:

A61N1/00A61N1/30

Patent Drawings (7 sheets)

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] The present application is a continuation-in-part of U.S. patent application Ser. No. 11/129,765, filed on May 13, 2005, now U.S. Pat. No. 7,653,438 which claims the benefit of U.S. Provisional Application Nos. 60/616,254, filed on Oct. 5, 2004; and 60/624,793, filed on Nov. 2, 2004. Further, this application is a continuation-in-part of U.S. patent application Ser. No. 10/408,665, filed on Apr. 8, 2003 (published as United States Patent Publication 2003/0216792 on Nov. 20, 2003 now U.S. Pat. No. 7,162,303), which claims the benefit of U.S. Provisional Patent Application Nos. 60/442,970, filed on Jan. 29, 2003; 60/415,575, filed on Oct. 3, 2002; and 60/370,190, filed on Apr. 8, 2002. Further, the present application is a continuation-in-part of co-pending U.S. patent application Ser. No. 11/189,563, filed on Jul. 25, 2005.

INCORPORATION BY REFERENCE

[0002] All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

TECHNICAL FIELD

[0003] The present invention relates to methods and apparatus for neuromodulation. More particularly, the present invention relates to methods and apparatus for achieving neuromodulation via an intravascularly-delivered pulsed electric field.

BACKGROUND

[0004] Congestive Heart Failure (“CHF”) is a condition that occurs when the heart becomes damaged and reduces blood flow to the organs of the body. If blood flow decreases sufficiently, kidney function becomes impaired, which results in fluid retention, abnormal hormone secretions and increased constriction of blood vessels. These results increase the workload of the heart and further decrease the capacity of the heart to pump blood through the kidneys and circulatory system.

[0005] It is believed that progressively decreasing perfusion of the kidneys is a principal non-cardiac cause perpetuating the downward spiral of CHF. Moreover, the fluid overload and associated clinical symptoms resulting from these physiologic changes result in additional hospital admissions, poor quality of life and additional costs to the health care system.

[0006] In addition to their role in the progression of CHF, the kidneys play a significant role in the progression of Chronic Renal Failure (“CRF”), End-Stage Renal Disease (“ESRD”), hypertension (pathologically high blood pressure) and other cardio-renal diseases. The functions of the kidneys can be summarized under three broad categories: filtering blood and excreting waste products generated by the body's metabolism; regulating salt, water, electrolyte and acid-base balance; and secreting hormones to maintain vital organ blood flow. Without properly functioning kidneys, a patient will suffer water retention, reduced urine flow and an accumulation of waste toxins in the blood and body. These conditions result from reduced renal function or renal failure (kidney failure) and are believed to increase the workload of the heart. In a CHF patient, renal failure will cause the heart to further deteriorate as fluids are retained and blood toxins accumulate due to the poorly functioning kidneys.

[0007] It has been established in animal models that the heart failure condition results in abnormally high sympathetic activation of the kidneys. An increase in renal sympathetic nerve activity leads to vasoconstriction of blood vessels supplying the kidneys, decreased renal blood flow, decreased removal of water and sodium from the body, and increased renin secretion. Reduction of sympathetic renal nerve activity, e.g., via denervation, may reverse these processes.

[0008] Applicants have previously described methods and apparatus for treating renal disorders by applying a pulsed electric field to neural fibers that contribute to renal function. See, for example, co-pending U.S. patent application Ser. No. 11/129,765, filed on May 13, 2005, and Ser. No. 11/189,563, filed on Jul. 25, 2005, now abandoned, both of which are incorporated herein by reference in their entireties. A pulsed electric field (PEF) may initiate renal neuromodulation, e.g., denervation, for example, via irreversible electroporation or via electrofusion. The PEF may be delivered from apparatus positioned intravascularly, extravascularly, transvascularly or a combination thereof. As used herein, electrofusion comprises fusion of neighboring cells induced by exposure to an electric field. Contact between target neighboring cells for the purposes of electrofusion may be achieved in a variety of ways, including, for example, via dielectrophoresis. In tissue, the target cells may already be in contact, facilitating electrofusion.

[0009] As used herein, electroporation and electropermeabilization are methods of manipulating the cell membrane or intracellular apparatus. For example, the porosity of a cell membrane may be increased by inducing a sufficient voltage across the cell membrane through, e.g., short, high-voltage pulses. The extent of porosity in the cell membrane (e.g., size and number of pores) and the duration of effect (e.g., temporary or permanent) are a function of multiple variables, such as field strength, pulse width, duty cycle, electric field orientation, cell type or size and other parameters.

[0010] Cell membrane pores will generally close spontaneously upon termination of relatively lower strength electric fields or relatively shorter pulse widths (herein defined as “reversible electroporation”). However, each cell or cell type has a critical threshold above which pores do not close such that pore formation is no longer reversible; this result is defined as “irreversible electroporation,” “irreversible breakdown” or “irreversible damage.” At this point, the cell membrane ruptures and/or irreversible chemical imbalances caused by the high porosity occur. Such high porosity can be the result of a single large hole and/or a plurality of smaller holes.

[0011] In some patients, when a PEF sufficient to initiate irreversible electroporation is applied to renal nerves and/or other neural fibers that contribute to renal neural functions, applicants believe that denervation induced by the PEF would result in increased urine output, decreased plasma renin levels, decreased tissue (e.g., kidney) and/or urine catecholamines (e.g., norepinephrine), increased urinary sodium excretion, and/or controlled blood pressure. Such responses would prevent or treat CHF, hypertension, renal system diseases, and other renal or cardio-renal anomalies. PEF systems could be used to modulate efferent or afferent nerve signals, as well as combinations of efferent and afferent nerve signals.

[0012] A potential challenge of using intravascular PEF systems for treating renal disorders is to selectively electroporate target cells without affecting other cells. For example, it may be desirable to irreversibly electroporate renal nerve cells that travel along or in proximity to renal vasculature, but it may not be desirable to damage the smooth muscle cells of which the vasculature is composed. As a result, an overly aggressive course of PEF therapy may persistently injure the renal vasculature, but an overly conservative course of PEF therapy may not achieve the desired renal neuromodulation.

[0013] Applicants have previously described methods and apparatus for monitoring tissue impedance or conductivity to determine the effects of pulsed electric field therapy, e.g., to determine an extent of electroporation and/or its degree of irreversibility. See, for example, Applicant's co-pending U.S. patent application Ser. No. 11/233,814, filed Sep. 23, 2005 now abandoned, incorporated by reference as set forth above. Pulsed electric field electroporation of tissue causes a decrease in tissue impedance and an increase in tissue conductivity. If induced electroporation is reversible, tissue impedance and conductivity should approximate baseline levels upon cessation of the pulsed electric field. However, if electroporation is irreversible, impedance and conductivity changes should persist after terminating the pulsed electric field. Thus, monitoring the impedance or conductivity of target and/or non-target tissue may be utilized to determine the onset of electroporation and to determine the type or extent of electroporation. Furthermore, monitoring data may be used in one or more manual or automatic feedback loops to control the electroporation.

[0014] Even when monitoring techniques are utilized, the applied energy or voltage from an intravascular PEF system necessary to establish an electric field of sufficient magnitude to modulate target neural fibers that contribute to renal function may be of a magnitude that causes persistent damage to non-target tissue, such as smooth muscle cells of the vessel wall. Thus, a desired treatment outcome, e.g., renal denervation, may not be achievable with some intravascular PEF systems in certain patients without concomitantly inducing persistent damage to the non-target tissue. It therefore would be desirable to provide methods and apparatus for reducing the required magnitude of applied voltage delivered from an intravascular PEF system necessary to achieve desired neuromodulation in target tissue.

SUMMARY

[0015] The present invention provides methods and apparatus for achieving neuromodulation via an intravascularly-delivered pulsed electric field (“PEF”). In some embodiments, the intravascular PEF system comprises a catheter having a pair of bipolar electrodes for delivering the PEF, with a first electrode positioned on a first side of an impedance-altering element and a second electrode positioned on an opposing side of the impedance-altering element. A length of the electrodes as well as a separation distance between the first and second electrodes may be specified such that, with the impedance-altering element deployed in a manner that locally increases impedance within a patient's vessel, a magnitude of applied voltage delivered across the bipolar electrodes necessary to achieve desired neuromodulation is reduced relative to an intravascular PEF system having similarly spaced electrodes but no (or an undeployed) impedance-altering element. For example, the impedance-altering element can be deployed to contact the vessel wall at a treatment site within the patient's vasculature to locally increase the impedance within a vessel. In a preferred embodiment, the impedance-altering element comprises an inflatable balloon configured to locally increase impedance within a patient's vasculature. The methods and apparatus of the present invention may be used to modulate a neural fiber that contributes to renal function.

[0016] Pulsed electric field parameters may be altered and combined in any combination, as desired. Such parameters can include, but are not limited to, voltage, field strength, pulse width, pulse duration, the shape of the pulse, the number of pulses and/or the interval between pulses (e.g., duty cycle), etc. Suitable field strengths include, for example, strengths of up to about 10,000 V/cm. Suitable pulse widths include, for example, widths of up to about 1 second. Suitable shapes of the pulse waveform include, for example, AC waveforms, sinusoidal waves, cosine waves, combinations of sine and cosine waves, DC waveforms, DC-shifted AC waveforms, RF waveforms, square waves, trapezoidal waves, exponentially-decaying waves, combinations thereof, etc. Suitable numbers of pulses include, for example, at least one pulse. Suitable pulse intervals include, for example, intervals less than about 10 seconds. These parameters are provided for the sake of illustration and should in no way be considered limiting.

BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Several embodiments of the present invention will be apparent upon consideration of the following detailed description, taken in conjunction with the accompanying drawings, in which like reference characters refer to like parts throughout, and in which:

[0018] FIG. 1 is a schematic view illustrating human renal anatomy.

[0019] FIG. 2 is a schematic detail view showing the location of the renal nerves relative to the renal artery.

[0020] FIGS. 3A and 3B are schematic side- and end-views, respectively, illustrating orienting of an electric field for selectively affecting renal nerves.

[0021] FIG. 4 is a schematic view illustrating an exemplary intravascular method and apparatus for renal neuromodulation.

[0022] FIG. 5 is a schematic view illustrating an intravascular method and apparatus of the present invention.

[0023] FIG. 6 is a schematic view illustrating an alternative intravascular method and apparatus of the present invention.

[0024] FIGS. 7A-7D are schematic cross-sectional views illustrating Finite Element Analysis modeling of spatial distributions of field strength for various intravascular PEF systems upon application of a constant magnitude applied voltage across bipolar electrodes of the PEF systems while the electrodes are positioned within a patient's renal artery.

[0025] FIG. 8 is a graph illustrating modeling estimates of induced field strength along the renal artery/fat interface with the PEF systems of FIG. 7.

DETAILED DESCRIPTION

A. Overview

[0026] The present invention relates to methods and apparatus for neuromodulation, e.g., denervation. More particularly, the present invention relates to methods and apparatus for achieving neuromodulation via an intravascularly-delivered pulsed electric field. In some embodiments, the intravascular PEF system comprises a catheter having a pair of bipolar electrodes for delivering the PEF, with a first electrode positioned on a first side of an impedance-altering element and a second electrode positioned on an opposing side of the impedance-altering element. A length of the electrodes, as well as a separation distance between the first and second electrodes, may be specified such that a magnitude of applied voltage delivered across the bipolar electrodes necessary to achieve desired neuromodulation is reduced relative to an intravascular PEF system having similarly spaced electrodes but no (or an undeployed) impedance-altering element.

[0027] The methods and apparatus of the present invention may be used to modulate a neural fiber that contributes to renal function and may exploit any suitable electrical signal or field parameters, e.g., any electric field that will achieve the desired neuromodulation (e.g., electroporative effect). To better understand the structures of devices of the present invention and the methods of using such devices for renal neuromodulation and monitoring, it is instructive to examine the renal anatomy in humans.

B. Selected Embodiments of Methods for Neuromodulation

[0028] With reference now to FIG. 1, the human renal anatomy includes kidneys K that are supplied with oxygenated blood by renal arteries RA, which are connected to the heart by the abdominal aorta AA. Deoxygenated blood flows from the kidneys to the heart via renal veins RV and the inferior vena cava IVC. FIG. 2 illustrates a portion of the renal anatomy in greater detail. More specifically, the renal anatomy also includes renal nerves RN extending longitudinally along the lengthwise dimension L of renal artery RA generally within the adventitia of the artery. The renal artery RA has smooth muscle cells SMC that surround the arterial circumference and spiral around the angular axis θ of the artery. The smooth muscle cells of the renal artery accordingly have a lengthwise or longer dimension extending transverse (i.e., non-parallel) to the lengthwise dimension of the renal artery. The misalignment of the lengthwise dimensions of the renal nerves and the smooth muscle cells is defined as “cellular misalignment.”

[0029] Referring to FIG. 3, the cellular misalignment of the renal nerves and the smooth muscle cells may be exploited to selectively affect renal nerve cells with reduced effect on smooth muscle cells. More specifically, because larger cells require a lower electric field strength to exceed the cell membrane irreversibility threshold voltage or energy for irreversible electroporation, several embodiments of electrodes of the present invention are configured to align at least a portion of an electric field generated by the electrodes with or near the longer dimensions of the cells to be affected. In specific embodiments, the device has electrodes configured to create an electrical field aligned with or near the lengthwise dimension L of the renal artery RA to affect renal nerves RN. By aligning an electric field so that the field preferentially aligns with the lengthwise aspect of the cell rather than the diametric or radial aspect of the cell, lower field strengths may be used to affect target neural cells, e.g., to necrose or fuse the target cells, to induce apoptosis, to alter gene expression, to change cytokine upregulation, etc. This is expected to reduce total energy delivered to the system and to mitigate effects on non-target cells in the electric field.

[0030] Similarly, the lengthwise or longer dimensions of tissues overlying or underlying the target nerve are orthogonal or otherwise off-axis (e.g., transverse) with respect to the longer dimensions of the nerve cells. Thus, in addition to aligning the PEF with the lengthwise or longer dimensions of the target cells, the PEF may propagate along the lateral or shorter dimensions of the non-target cells (i.e., such that the PEF propagates at least partially out of alignment with non-target smooth muscle cells SMC). Therefore, as seen in FIG. 3, applying a PEF with propagation lines Li generally aligned with the longitudinal dimension L of the renal artery RA is expected to preferentially cause electroporation, electrofusion, denervation or other neuromodulation in cells of the target renal nerves RN without unduly affecting the non-target arterial smooth muscle cells SMC. The pulsed electric field may propagate in a single plane along the longitudinal axis of the renal artery, or may propagate in the longitudinal direction along any angular segment θ through a range of 0°-360°.

[0031] A PEF system placed within and/or at least partially across the wall of the renal artery may propagate an electric field having a longitudinal portion that is aligned to run with the longitudinal dimension of the artery in the region of the renal nerves RN and the smooth muscle cell SMC of the vessel wall so that the wall of the artery remains at least substantially intact while the outer nerve cells are destroyed, fused or otherwise affected. Monitoring elements may be utilized to assess an extent of, e.g., electroporation, induced in renal nerves and/or in smooth muscle cells, as well as to adjust PEF parameters to achieve a desired effect.

C. Exemplary Embodiments of Systems and Additional Methods for Neuromodulation

[0032] With reference to FIG. 4, an embodiment of an intravascular PEF system and method is described. The system is configured for temporary intravascular placement. Furthermore, the system is configured to deliver a pulsed electric field to neural fibers for neuromodulation, e.g., to deliver the pulsed electric field to neural fibers that contribute to renal function in order to achieve renal neuromodulation. Intravascular pulsed electric field apparatus 100 comprises catheter 102 having a pair of bipolar electrodes 104 positioned along the shaft of the catheter. The electrodes are electrically connected to pulsed electric field generator 50 located external to the patient. The generator may be utilized with any embodiment of the present invention for delivery of a PEF with desired field parameters. It should be understood that PEF-delivery electrodes of embodiments described hereinafter may be electrically connected to the generator, even though the generator is not explicitly shown or described with each embodiment. The electrodes may, for example, be fabricated from wound coils of wire. When utilizing relatively long electrodes, wound coils allow the catheter to maintain a desired degree of flexibility.

[0033] In use, catheter 102 may, for example, be delivered to renal artery RA as shown, or may be delivered to a renal vein or to any other vessel in proximity to neural tissue contributing to renal function, for example, through a guide catheter. Once positioned within the patient's vasculature, a pulsed electric field may be generated by the PEF generator 50, transferred through catheter 102 to electrodes 104, and delivered via the electrodes 104 across the wall of the vasculature. The PEF therapy modulates the activity along neural fibers, for example, along neural fibers that contribute to renal function, e.g., denervates the neural fibers. This may be achieved, for example, via irreversible electroporation, electrofusion, necrosis and/or inducement of apoptosis in the nerve cells, alteration of gene expression, changes in cytokine upregulation, etc. In many applications, including that shown in FIG. 4, the electrodes are arranged so that the pulsed electric field is aligned with the longitudinal dimension of the renal artery to facilitate modulation of renal nerves with limited effect on non-target smooth muscle cells or other cells.

[0034] It is expected that PEF therapy will alleviate clinical symptoms of CHF, hypertension, renal disease and/or other cardio-renal diseases for a period of months, potentially up to six months or more. This time period might be sufficient to allow the body to heal; for example, this period might reduce the risk of CHF onset after an acute myocardial infarction, thereby alleviating a need for subsequent re-treatment. Alternatively, as symptoms reoccur, or at regularly scheduled intervals, the patient might return to the physician for a repeat therapy.

[0035] In order to denervate target neural fibers, apparatus 100 must generate an electric field of sufficient strength or magnitude across the fibers to induce such denervation. Depending upon the arrangement and positioning of electrodes 104 and catheter 102, as well as the physiology of the patient, the applied voltage necessary to achieve a field strength of sufficient magnitude at the neural fibers might also be of sufficient magnitude to induce undesirable persistent injury in non-target tissue, such as smooth muscle cells and/or the vessel wall. It therefore would be desirable to provide apparatus and methods that reduce the necessary applied voltage for intravascular renal denervation via PEF therapy, as compared to the applied voltage required when utilizing apparatus 100.

[0036] Referring now to FIG. 5, an embodiment of an intravascular PEF system of the present invention is described. This embodiment includes an apparatus 200 comprising a catheter 202 having impedance-altering element 204, such as an inflatable balloon, an expandable cage (e.g., a polymer-coated expandable wire cage) or some other expandable element. Several embodiments of the impedance altering element 204 are configured to center electrodes 206 within a vessel. In a preferred embodiment, impedance-altering element 204 is configured to locally increase impedance within a patient's vasculature. In a further preferred embodiment, impedance-altering element 204 comprises an inflatable balloon, as shown in FIG. 5.

[0037] PEF-delivery electrodes 206a and 206b are positioned along the shaft of catheter 202 with known separation distance D; and optional radiopaque markers 208 are positioned along the shaft of the catheter in the region of impedance-altering element 204. The radiopaque markers 208 can be spaced apart from each other along a balloon-type impedance-altering element by known separation distance d. The electrodes 206a-b, for example, can be arranged such that the electrode 206a is near a proximal end of element 204 and the electrode 206b is near a distal end of the element 204. Electrodes 206 are electrically coupled to pulse generator 50 (see FIG. 4), which is positioned external to the patient, for delivery of PEF therapy. Radiopaque markers additionally or alternatively may be located along the shaft of catheter 202 outside of element 204, as illustrated by radiopaque markets 208′. As yet another alternative or addition, electrodes 206 may be fabricated from a radiopaque material, such as platinum, and utilized as radiopaque markers.

[0038] Apparatus 200 may further comprise optional monitoring electrodes 210, illustratively also with known separation distance d. Applicants have previously described the use of such monitoring electrodes to monitor tissue impedance or conductivity for determining the effects of pulsed electric field therapy, e.g., for determining an extent of electroporation and/or its degree of irreversibility. See, for example, Applicant's co-pending U.S. patent application Ser. No. 11/233,814, filed Sep. 23, 2005 now abandoned, which is incorporated herein by reference as set forth above. Pulsed electric field electroporation of tissue causes a decrease in tissue impedance and an increase in tissue conductivity. If induced electroporation is reversible, tissue impedance and conductivity should approximate baseline levels upon cessation of the pulsed electric field. However, if electroporation is irreversible, impedance and conductivity changes should persist after termination of the pulsed electric field. Thus, monitoring of the impedance or conductivity of target and/or non-target tissue via electrodes 210 may be utilized to determine the onset of electroporation and/or to determine the type or extent of electroporation. Furthermore, monitoring data may be used in one or more manual or automatic feedback loops to control the electroporation.

[0039] Regardless of whether the effects of PEF therapy are monitored, the magnitude of voltage applied across electrodes 206 in order to establish an electric field of sufficient magnitude to modulate target neural fibers that contribute to renal function also might be of a magnitude that causes persistent damage to non-target tissue, such as smooth muscle cells of the vessel wall. Thus, a desired treatment outcome, e.g., renal denervation, might not be achievable in certain patients without concomitantly inducing persistent damage to the non-target tissue.

[0040] In accordance with the principles of the present invention, impedance-altering element 204 may reduce the magnitude of voltage applied across electrodes 206 that is required to modulate the target neural fibers. In some patients, this reduction in magnitude might lower the applied voltage below a threshold level that would cause the undesirable persistent damage to the non-target tissue. Element 204 may achieve this reduction in applied voltage magnitude, for example, by locally increasing impedance within the renal vasculature. Element 204 additionally or alternatively may facilitate use of a common applied voltage across a wider range of vessel sizes.

[0041] In embodiments where the impedance-altering element 204 comprises an inflatable balloon configured to temporarily occlude blood flow during delivery of PEF therapy across electrodes 206, the occluding balloon may serve as an electrical insulator that locally increases electrical impedance during PEF delivery. This impedance increase may direct an electric field delivered across electrodes 206, e.g., may direct the electric field into or across the vessel wall for modulation of target neural fibers. The impedance-altering element 204 electrically insulates a portion of the vessel in a manner that may reduce the magnitude of applied voltage or other parameters of the pulsed electric field necessary to achieve a desired field strength at the target fibers compared to apparatus 100 of FIG. 4 that does not comprise an impedance-altering element. The desired field strength, for example, may have a magnitude sufficient to denervate the target fibers via electroporation. As discussed, this reduction may moderate persistent damage to the non-target tissue. Furthermore, by substantially centering electrodes 206 within the vessel before delivery of PEF therapy, element 204 may further reduce a potential of persistent damage to the non-target tissue of the vessel wall, etc., and/or may facilitate delivery of a more concentrically uniform electric field to the target neural fibers surrounding the renal artery. In addition, or as an alternative, to the use of balloon element 204 to achieve a desired insulation or impedance increase within a patient's vasculature between electrodes 206 during delivery of PEF therapy, the impedance change may be achieved via an insulative covering, e.g., via a polymeric tube or sleeve with closed ends, positioned about a mechanical activation member. The mechanical activation member may be configured to expand the insulative covering into, e.g., circumferential sealing contact with the vessel wall. The mechanical activation member may, for example, comprise an expandable cage. Additional methods and apparatus in accordance with the present invention for achieving the desired impedance change will be apparent to those of skill in the art.

[0042] With reference now to FIG. 6, an alternative embodiment of apparatus 200 is described. In FIG. 5, impedance-altering element 204 illustratively comprises a semi-compliant balloon that contacts renal artery RA over a length of the artery. In FIG. 6, element 204′ illustratively comprises a substantially non-compliant balloon that contacts the renal artery more focally, e.g., substantially tangentially. Balloon element 204′ of FIG. 6 may have a shorter length than balloon element 204 of FIG. 5, thereby facilitating a shorter separation distance D between PEF-delivery electrodes 206.

[0043] Finite Element Analysis (“FEA”) modeling of induced electric field strengths from various embodiments of intravascular PEF systems has been conducted to guide the design of preferred intravascular PEF system embodiments that reduce the required applied voltage needed to achieve a desired field strength at target tissue. Modeled variables of the intravascular PEF system designs included use (or lack thereof) of an element configured to locally increase impedance within a patient's vasculature (e.g., a balloon element), the physical design of the impedance-altering element, electrode size (not shown) and electrode spacing (not shown). Varying vessel diameter also was modeled.

[0044] With reference to FIGS. 7 and 8, the FEA modeling results for four exemplary intravascular PEF systems are provided. Each of the four systems was modeled with a constant applied voltage across the electrodes (e.g., 360V), a constant electrode size (e.g., 6 mm), and a constant electrode separation distance (e.g., 10 mm) within a vessel of constant diameter (e.g., 3.5 mm). These models facilitate study of the effect of the design of the impedance-altering element on induced field strength at target tissue. In FIGS. 7 and 8, the PEF electrodes illustratively are centered with the vessel. The impedance-altering element preferably facilitates centering of the electrodes within the vessel.

[0045] As seen in FIG. 7A, the first PEF system embodiment comprises a variation of apparatus 100 of FIG. 4 that does not comprise an impedance-altering element or that comprises an undeployed impedance-altering element, such as a deflated balloon element. As seen in FIG. 7B, the second embodiment comprises a variation of apparatus 200 of FIG. 5 comprising a 5 mm-long balloon element configured to alter impedance within a patient's vasculature, illustratively a semi-compliant balloon. In FIG. 7C, the third embodiment comprises a variation of apparatus 200 of FIG. 6 wherein balloon element 204′ is 4 mm long, illustratively non-compliant, and makes only tangential contact with the wall of the renal artery RA. In FIG. 7D, the fourth embodiment comprises another variation of apparatus 200 wherein the balloon element 204″ comprises a disc that occludes the renal artery RA over a very short length and makes substantially tangential wall contact.

[0046] The four embodiments each comprise a pair of bipolar PEF-delivery electrodes (electrodes 104 in FIG. 7A and electrodes 206 in FIGS. 7B-7D) with a constant separation distance D between each of the electrodes e.g., 10 mm), and a constant electrode length L (e.g., 6 mm). Similar modeling was conducted with a separation distance of 20 mm between the electrodes (not shown), and it was determined that a separation distance of less than about 20 mm is desirable in order to significantly alter the requisite magnitude of applied voltage needed with an inflated balloon to achieve a desired field strength magnitude along target neural tissue. Use of a balloon element when the electrode spacing was about 20 mm or greater showed little difference in required applied voltage between when a balloon was, and was not, used.

[0047] Electrodes 206 illustratively comprise 6 mm electrodes. Modeling also was conducted with 3 mm electrodes (not shown), and it was determined that the required applied voltage for a given field strength at target tissue generally increases as electrode length decreases. Thus, it generally is desirable to have longer electrodes, for example, electrodes preferably longer than about 1 mm, even more preferably longer than about 2 mm.

[0048] FIG. 8 provides a graph illustrating modeling estimates of induced field strength in the vicinity of target neural fibers along the renal artery RA/fat F interface I when 360V are applied across modeled bipolar electrodes of the modeled PEF system embodiments of FIG. 7. FIGS. 7 and 8 illustrate that, for the modeled PEF system designs, use of an impedance-altering element such as a balloon directs the electrical field across the wall of the renal artery. Furthermore, the peak field strength induced in the vicinity of the target neural fibers, i.e., at interface I, is increased. Thus, a lower applied voltage may be required to obtain a desired peak electric field strength at interface I when an impedance-altering element is utilized, as compared to when no impedance-altering element is provided or when the impedance-altering element is not deployed (e.g., when a balloon element is not inflated).

[0049] The modeled systems of FIGS. 7 and 8 illustrate that the contact length between the impedance-altering element and the vessel wall does not substantially alter the peak electric field strength at the interface, so long as some wall contact exists. Furthermore, shorter contact lengths, e.g., contact lengths achieved with balloon elements having lengths of less than about 5 mm, do not substantially alter the peak electric field strength. Additional FEA models (not shown) illustrate that, for the 10 mm spacing of the bipolar electrodes and a given applied voltage, use of an impedance-altering element substantially reduces changes in peak electric field strength associated with changes in vessel diameter, as compared to PEF systems without, or with undeployed, impedance-altering elements, suggesting that a substantially constant applied voltage may be used to achieve a desired electric field strength over a variety of vessel sizes when an impedance-altering element is used. This is in contrast to PEF system embodiments lacking impedance-altering elements; such embodiments might require increasing applied voltages with increasing vessel diameter in order to achieve a given desired peak electric field strength. The range of vessel sizes over which an impedance-altering PEF system may apply a substantially constant voltage to achieve a substantially similar peak field strength at the interface may, for example, vary between about 3 mm and 9 mm.

[0050] Although preferred illustrative variations of the present invention are described above, it will be apparent to those skilled in the art that various changes and modifications may be made thereto without departing from the invention. For example, although the variations primarily have been described for use in combination with pulsed electric fields, it should be understood that any other electric field may be delivered as desired. It is intended in the appended claims to cover all such changes and modifications that fall within the true spirit and scope of the invention.

Claims

We claim:

1. An apparatus for intravascularly-induced neuromodulation, the apparatus comprising:

an electric field generator; and

an intravascular catheter comprising a shaft, an impedance-altering element, and a pair of bipolar electrodes positioned on the shaft on opposite sides of the impedance-altering element, wherein the impedance-altering element comprises an expandable, vessel occluding member;

a first lead connected between one of the electrodes and a first terminal on the electric field generator;

a second lead connected between the other one of the electrodes and a second terminal of opposite polarity on the electric field generator;

at least one monitoring electrode carried by the impedance-altering element; and

a current supply connected to said monitoring electrode for supplying current for monitoring a tissue property,

wherein (a) the apparatus is configured for intravascular delivery of an electric field across the bipolar electrodes, and (b) the impedance-altering element is configured to locally increase impedance within a patient's vasculature between the bipolar electrodes during intravascular delivery of the electric field.

2. The apparatus of claim 1, wherein the impedance-altering element is configured to temporarily occlude blood flow within the patient's vasculature.

3. The apparatus of claim 2, wherein the impedance-altering element comprises a balloon element.

4. The apparatus of claim 3, wherein the balloon element comprises a compliant or semi-compliant balloon.

5. The apparatus of claim 3, wherein the balloon element comprises a non-compliant balloon.

6. The apparatus of claim 1, wherein the separation distance between the bipolar electrodes is not greater than about 20 mm.

7. The apparatus of claim 1, wherein each of the bipolar electrodes comprises a length of at least about 1 mm.

8. The apparatus of claim 1 wherein the at least one monitoring electrode is carried by an external surface of the impedance-altering element and is positioned to contact a vessel wall.

9. The apparatus of claim 8, wherein the monitoring electrode is configured to monitor a treatment effect in tissue exposed to the electric field.

10. The apparatus of claim 8, wherein the monitoring electrode is configured to monitor impedance of tissue proximate to the monitoring electrode.

11. The apparatus of claim 1, wherein the impedance-altering element is configured to substantially center the bipolar electrodes within the patient's vasculature.

12. The apparatus of claim 1, wherein the apparatus is configured for intravascular delivery of the electric field to neural fibers that contribute to renal function in order to modulate the neural fibers.

13. The apparatus of claim 1, wherein the impedance-altering element comprises an insulative covering positioned about a mechanical activation member.

14. The apparatus of claim 1, wherein the impedance altering element is configured to locally increase impedance within the patient's vasculature along a segment of the vasculature having a length of less than about 20 mm.

15. The apparatus of claim 1, wherein the electric field generator is configured to deliver a pulsed electric field via the electrode.

16. The apparatus of claim 15 wherein the at least one monitoring electrode is carried by an external surface of the impedance-altering element and is positioned to contact a vessel wall.

17. The apparatus of claim 16, wherein the monitoring electrode is configured to monitor electroporation induced in a target tissue by the pulsed electric field.

18. The apparatus of claim 16, wherein the monitoring electrode is configured to monitor electroporation induced in a non-target tissue by the pulsed electric field.

19. The apparatus of claim 1, wherein the electric field generator is configured to deliver energy to a target tissue via the electrode, and wherein the energy is sufficient to denervate the target tissue.

Patent Citations (163)

Patent	Date	Inventor	Cited By
US3650277(A)	1972-03-01	Sjostrand et al.	Applicant
US3774620(A)	1973-11-01	Hansjurgens	Applicant
US3895639(A)	1975-07-01	Rodler	Applicant
US5006119(A)	1991-04-01	Acker et al.	Applicant
US5019034(A)	1991-05-01	Weaver et al.	Examiner
US5094242(A)	1992-03-01	Gleason et al.	Applicant
US5125928(A)	1992-06-01	Parins et al.	Applicant
US5193539(A)	1993-03-01	Schulman et al.	Applicant
US5193540(A)	1993-03-01	Schulman et al.	Applicant
US5203326(A)	1993-04-01	Collins et al.	Applicant
US5213098(A)	1993-05-01	Bennett et al.	Applicant
US5282785(A)	1994-02-01	Shapland et al.	Applicant
US5286254(A)	1994-02-01	Shapland et al.	Applicant
US5304120(A)	1994-04-01	Crandell et al.	Applicant
US5324255(A)	1994-06-01	Passafaro et al.	Applicant
US5324316(A)	1994-06-01	Schulman et al.	Applicant
US5334193(A)	1994-08-01	Nardella	Applicant
US5338662(A)	1994-08-01	Sadri	Applicant
US5405367(A)	1995-04-01	Schulman et al.	Applicant
US5458568(A)	1995-10-01	Racchini et al.	Applicant
US5458626(A)	1995-10-01	Krause	Applicant
US5472406(A)	1995-12-01	de la Torre et al.	Applicant
US5494822(A)	1996-02-01	Sadri	Applicant
US5498238(A)	1996-03-01	Shapland et al.	Applicant
US5499971(A)	1996-03-01	Shapland et al.	Applicant
US5507724(A)	1996-04-01	Hofmann et al.	Applicant
US5553611(A)	1996-09-01	Budd et al.	Examiner
US5569198(A)	1996-10-01	Racchini	Applicant
US5571147(A)	1996-11-01	Sluijter et al.	Applicant
US5626576(A)	1997-05-01	Janssen	Applicant
US5628730(A)	1997-05-01	Shapland et al.	Applicant
US5634899(A)	1997-06-01	Shapland et al.	Applicant
US5690691(A)	1997-11-01	Chen et al.	Applicant
US5725563(A)	1998-03-01	Klotz	Applicant
US5792187(A)	1998-08-01	Adams	Applicant
US5807306(A)	1998-09-01	Shapland et al.	Applicant
US5861021(A)	1999-01-01	Thome et al.	Applicant
US5865787(A)	1999-02-01	Shapland et al.	Examiner
US5871449(A)	1999-02-01	Brown	Applicant
US5906636(A)	1999-05-01	Casscells, III et al.	Applicant
US5916154(A)	1999-06-01	Hobbs et al.	Applicant
US5919187(A)	1999-07-01	Guglielmi et al.	Applicant
US5924997(A)	1999-07-01	Campbell	Applicant
US5935075(A)	1999-08-01	Casscells et al.	Applicant
US6026326(A)	2000-02-01	Bardy	Applicant
US6051017(A)	2000-04-01	Loeb et al.	Applicant
US6058328(A)	2000-05-01	Levine et al.	Applicant
US6245026(B1)	2001-06-01	Campbell et al.	Applicant
US6251130(B1)	2001-06-01	Dobak, III et al.	Applicant
US6272377(B1)	2001-08-01	Sweeney et al.	Applicant
US6287608(B1)	2001-09-01	Levin et al.	Applicant
US6347247(B1)	2002-02-01	Dev et al.	Applicant
US6400982(B2)	2002-06-01	Sweeney et al.	Applicant
US6464687(B1)	2002-10-01	Ishikawa et al.	Applicant
US6482619(B1)	2002-11-01	Rubinsky et al.	Applicant
US6536949(B1)	2003-03-01	Heuser	Applicant
US6571127(B1)	2003-05-01	Ben-Haim et al.	Applicant
US6601459(B1)	2003-08-01	Jenni et al.	Applicant
US6613045(B1)	2003-09-01	Laufer et al.	Examiner
US6615071(B1)	2003-09-01	Casscells, III et al.	Applicant
US6786904(B2)	2004-09-01	Doscher et al.	Applicant
US6927049(B2)	2005-08-01	Rubinsky et al.	Applicant
US6936047(B2)	2005-08-01	Nasab et al.	Examiner
US6969388(B2)	2005-11-01	Goldman et al.	Examiner
US7054685(B2)	2006-05-01	Dimmer et al.	Applicant
US7063679(B2)	2006-06-01	Maguire et al.	Applicant
US7081114(B2)	2006-07-01	Rashidi	Applicant
US7081115(B2)	2006-07-01	Taimisto	Applicant
US7083614(B2)	2006-08-01	Fjield et al.	Applicant
US7122019(B1)	2006-10-01	Kesten et al.	Applicant
US2002/0026228(A1)	2002-02-01	Schauerte	Applicant
US2003/0055422(A1)	2003-03-01	Lesh	Examiner
US2003/0150464(A1)	2003-08-01	Casscells	Applicant
US2003/0199747(A1)	2003-10-01	Michlitsch et al.	Applicant
US2003/0199767(A1)	2003-10-01	Cespedes et al.	Applicant
US2003/0199768(A1)	2003-10-01	Cespedes et al.	Applicant
US2003/0236443(A1)	2003-12-01	Cespedes et al.	Applicant
US2004/0064090(A1)	2004-04-01	Keren et al.	Applicant
US2004/0064091(A1)	2004-04-01	Keren et al.	Applicant
US2004/0101523(A1)	2004-05-01	Reitz et al.	Applicant
US2004/0163655(A1)	2004-08-01	Gelfand et al.	Applicant
US2004/0167415(A1)	2004-08-01	Gelfand et al.	Applicant
US2004/0176699(A1)	2004-09-01	Walker et al.	Applicant
US2004/0249416(A1)	2004-12-01	Yun et al.	Applicant
US2005/0010263(A1)	2005-01-01	Schauerte	Applicant
US2005/0080459(A1)	2005-04-01	Jacobson et al.	Applicant
US2005/0153885(A1)	2005-07-01	Yun et al.	Applicant
US2005/0171523(A1)	2005-08-01	Rubinsky et al.	Applicant
US2005/0171574(A1)	2005-08-01	Rubinsky et al.	Applicant
US2005/0171575(A1)	2005-08-01	Dev et al.	Applicant
US2005/0209548(A1)	2005-09-01	Dev et al.	Applicant
US2005/0209642(A1)	2005-09-01	Palti	Applicant
US2005/0240241(A1)	2005-10-01	Yun et al.	Applicant
US2006/0041283(A1)	2006-02-01	Gelfand et al.	Applicant
US2006/0067972(A1)	2006-03-01	Kesten et al.	Applicant
US2006/0069323(A1)	2006-03-01	Elkins et al.	Applicant
US2006/0074453(A1)	2006-04-01	Kieval et al.	Applicant
US2006/0079859(A1)	2006-04-01	Elkins et al.	Applicant
US2006/0085046(A1)	2006-04-01	Rezai et al.	Applicant
US2006/0089674(A1)	2006-04-01	Walters et al.	Applicant
US2006/0100667(A1)	2006-05-01	Machado et al.	Applicant
US2006/0111754(A1)	2006-05-01	Rezai et al.	Applicant
US2006/0116720(A1)	2006-06-01	Knoblich	Applicant
US2006/0121016(A1)	2006-06-01	Lee	Applicant
US2006/0135998(A1)	2006-06-01	Libbus et al.	Applicant
US2006/0136004(A1)	2006-06-01	Cowan et al.	Applicant
US2006/0155344(A1)	2006-07-01	Rezai et al.	Applicant
US2006/0189941(A1)	2006-08-01	Seward et al.	Applicant
US2006/0189960(A1)	2006-08-01	Kesten et al.	Applicant
US2006/0190044(A1)	2006-08-01	Libbus et al.	Applicant
US2006/0206149(A1)	2006-09-01	Yun	Applicant
US2006/0229677(A1)	2006-10-01	Moffitt et al.	Applicant
US2006/0235474(A1)	2006-10-01	Demarais	Applicant
US2006/0265015(A1)	2006-11-01	Demarais et al.	Applicant
DE3151180(A1)	1982-08-01		Applicant
EP811395(A2)	1997-06-01		Applicant
WO-85/01213	1985-03-01		Applicant
WO-91/04725	1991-04-01		Applicant
WO-93/02740	1993-02-01		Applicant
WO-93/07803	1993-04-01		Applicant
WO-94/00188	1994-01-01		Applicant
WO-95/33514	1995-12-01		Applicant
WO-96/04957	1996-02-01		Applicant
WO-96/11723	1996-04-01		Applicant
WO-97/13550	1997-04-01		Applicant
WO97/49453	1997-12-01		Applicant
WO-98/37926	1998-09-01		Applicant
WO-98/43700	1998-10-01		Applicant
WO-98/43701	1998-10-01		Applicant
WO-98/48888	1998-11-01		Applicant
WO-99/33407	1999-07-01		Applicant
WO-99/51286	1999-10-01		Applicant
WO-99/52424	1999-10-01		Applicant
WO-01/26729	2001-04-01		Applicant
WO-02/09808	2002-02-01		Applicant
WO-02/26314	2002-04-01		Applicant
WO-02/053207	2002-07-01		Applicant
WO-02/070039(A2)	2002-09-01		Applicant
WO-02/070047	2002-09-01		Applicant
WO-02/085448	2002-10-01		Applicant
WO-03/018108	2003-03-01		Applicant
WO-03/028802	2003-04-01		Applicant
WO-03/063692	2003-08-01		Applicant
WO-03/071140(A2)	2003-08-01		Applicant
WO-03/076008	2003-09-01		Applicant
WO-03/082080	2003-10-01		Applicant
WO-03/082403	2003-10-01		Applicant
WO-2004/026370	2004-04-01		Applicant
WO-2004/026371	2004-04-01		Applicant
WO-2004/026374	2004-04-01		Applicant
WO-2004/030718	2004-04-01		Applicant
WO-2004/032791	2004-04-01		Applicant
WO-2004/107965	2004-12-01		Applicant
WO-2005014100	2005-02-01		Applicant
WO-2005016165	2005-02-01		Applicant
WO-2005/032646	2005-04-01		Applicant
WO-2005/065284	2005-07-01		Applicant
WO-2005/084389(A2)	2005-09-01		Applicant
WO-2005/097256(A2)	2005-10-01		Applicant
WO-2005/123183	2005-12-01		Applicant
WO-2006/007048(A2)	2006-01-01		Applicant
WO-2006018528(A1)	2006-02-01		Applicant
WO-2006/031899(A2)	2006-03-01		Applicant

Non-Patent Literature (182)

U.S. Appl. No. 11/504,117, Demarais et al.Applicant
U.S. Appl. No. 11/599,649, Demarais et al.Applicant
U.S. Appl. No. 11/599,723, Demarais et al.Applicant
U.S. Appl. No. 11/599,882, Demarais et al.Applicant
U.S. Appl. No. 11/599,890, Demarais et al.Applicant
U.S. Appl. No. 11/688,178, Levin et al.Applicant
“Market for infusion pumps grows with an aging population,” NWL Jan. 1997, The BBI Newsletter, vol. 20, No. 2, Feb. 1, 1997, American Health Consultants Inc., 6 pages.Applicant
“PHCL 762 Pharmacology of the Autonomic Nervous System,” Chapter 2 and 6.8 in Mosby, http://www.kumc.edu/research/medicine/pharmacology/CAI/phcl762.html, last accessed Aug. 24, 2004, 14 pages.Applicant
“Programmable Infusion System,” Pumps and Pump Selection, Medtronic Pain Therapies, Medtronic, Inc. Sep. 5, 2001, 2 pages.Applicant
“Pulmonary Concepts in Critical Care Breath Sounds,” http://rnbob.tripod.com/breath.htm, last accessed Aug. 23, 2004, 5 pages.Applicant
“Pulmonary Function Testing,” http://jan.ucc.nau.edu/˜daa/lecture/pft.htm, last accessed Aug. 23, 2004, 8 pages.Applicant
“Renal Parenchymal Disease,” Ch. 26, 5th Edition Heart Disease, A Textbook of Cardiovascular Medicine vol. 2, Edited by Eugene Braunwald, WB Saunders Company, pp. 824-825.Applicant
“Sensorcaine-MPF Spinal Injection,” informational document, AstraZeneca 2001, 2 pages.Applicant
“Summary,” Critical Reviews in Biomedical Engineering, vol. 17, Issue 5, 1989, pp. 515-529.Applicant
“The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial,” ALLHAT Research Group, JAMA 2002, vol. 288, pp. 2981-2997.Applicant
Luff, S.E. et al., “Two types of sympathetic axon innervating the juxtaglomerular arterioles of the rabbit and rat kidney differ structurally from those supplying other arteries,” May 1, 1991, Journal of Neurocytology 1991, vol. 20, © 1991 Chapman and Hall Ltd., pp. 781-795.Applicant
Lundborg, C. et al., “Clinical experience using intrathecal (IT) bupivacaine infusion in three patients with complex regional pain syndrome type I (CRPS-I),” Acta Aneaesthesiol. Scand. 1999, vol. 43, pp. 667-678.Applicant
MacArthur, Dr. Alison, “Spinal Anesthesia and Severe Gestational Hypertension,” presentation at Mount Sinai Hospital, 25 pages.Applicant
Maeder, Micha, M.D. et al., “Contrast Nephropathy: Review Focusing on Prevention,” Jun. 22, 2004, Journal of the American College of Cardiology Nov. 2, 2004, vol. 44, No. 9, © 2004 by the American College of Cardiology Foundation, pp. 1763-1771.Applicant
Malpas, Simon C., “What sets the long-term level of sympathetic nerve activity: is there a role for arterial baroreceptors?” Invited Review, Am J Physiol Regul. Integr. Comp. Physiol. 2004, vol. 286, © 2004 the American Physiological Society, pp. R1-R12.Applicant
Marenzi, Giancarlo, M.D. et al., “The Prevention of Radiocontrast-Agent-Induced Nephropathy by Hemofiltration,” New England Journal of Medicine, Oct. 2, 2003, vol. 349 (14), © 2003 Massachusetts Medical Society, pp. 1333-1340.Applicant
Martin, Jason B. et al., “Gene Transfer to Intact Mesenteric Arteries by Electroporation,” Mar. 27, 2000, Journal of Vascular Research 2000, vol. 37, 2000 S. Karger AG, Basel, pp. 372-380.Applicant
McCreery, Douglas B. et al., “Charge Density and Charge Per Phase as Cofactors in Neural Injury Induced by Electrical Stimulation,” IEEE Transactions on Biomedical Engineering, vol. 17, No. 10, Oct. 1990, pp. 996-1000.Applicant
McCullough, Peter A., M.D., Mph et al., “Acute Renal Failure after Coronary Intervention: Incidence, Risk Factors and Relationship to Mortality,” Apr. 14, 1997, AM J Med. 1997, vol. 103, 1997 Excerpta Medica, Inc., pp. 368-375.Applicant
McMurray, John J.V., M.D. and Eileen O'Meara, M.D., “Treatment of Heart Failure with Spironolactone-Trial and Tribulations,” Aug. 5, 2004, New England Journal of Medicine, vol. 351, No. 6, © 2004 Massachusetts Medical Society, pp. 526-528.Applicant
McRobbie, D. and M.A. Foster, “Thresholds for biological effects of time-varying magnetic fields,” Dec. 16, 1983, Clin. Phys. Physiol. Meas. 1984, vol. 5, No. 2, © 1984, The Institute of Physics, pp. 67-78.Applicant
Medtronic Neurostimulation Systems, “Expanding the Array of Pain Control Solutions,” informational pamphlet, 1999 Medtronic, Inc., 6 pages.Applicant
Medtronic, “Spinal Cord Stimulation,” Patient Management Guidelines for Clinicians, Medtronic, Inc. 1999, 115 pages.Applicant
Medtronic, “SynchroMed Infusion System—Clinical Reference Guide for Pain Therapy,” Medtronic, Inc. 1998, 198 pages.Applicant
Mess, Sarah A., M.D. et al., “Implantable Baclofen Pump as an Adjuvent in Treatment of Pressure Sores,” Mar. 1, 2003, Annals of Plastic Surgery, vol. 51, No. 5, Nov. 2003, © 2003 Lippincott Williams & Wilkins, pp. 465-467.Applicant
Mihran, Richard T. et al., “Temporally-Specific Modification of Myelinated Axon Excitability in Vitro Following A Single Ultrasound Pulse,” Sep. 25, 1989, Ultrasound in Med.& Biol. 1990, vol. 16, No. 3, pp. 297-309.Applicant
Miklavcic, D. et al, “A Validated Model of in Vivo Electric Field Distribution in Tissues for Electrochemotherapy and for DNA Electrotransfer for Gene Therapy,” Biochimica et Biophysica Acta, 1523, 2000, pp. 73-83, www.elsevier.com/locate/bba.Applicant
Mitchell, G.A.G., “The Nerve Supply of the Kidneys,” Aug. 20, 1949, Acta Anatomica, vol. 10, Fasc. 1/2, 1950, pp. 1-37.Applicant
Moss, Nicholas G., “Renal function and renal afferent and efferent nerve activity,” Am J Physiol 1982, vol. 243, © 1982, the American Physiological Society, pp. F425-F433.Applicant
Munglani, Rajesh, “The longer term effect of pulsed radiofrequency for neuropathic pain,” Jun. 8, 1998, Pain, vol. 80, © 1999 International Association for the Study of Pain, Published by Elsevier Science B.V., pp. 437-439.Applicant
Naropin (ropivacaine HCl) injection, Rx only description, AstraZeneca 2001, 3 pages.Applicant
National High Blood Pressure Education Program, “1995 Update of the Working Group Reports on Chronic Renal Failure and Renovascular Hypertension,” presentation, 13 pages.Applicant
National Kidney Foundation, “Are You At Increased Risk for Chronic Kidney Disease?” © 2002 National Kidney Foundation, Inc., 14 pages.Applicant
Nelson, Lawrence D. and Jeffrey L. Osborn, “Neurogenic Control of Renal Function in Response to Graded Nonhypotensive Hemorrahage in Conscious Dogs,” Sep. 13, 1992, Am. J. Physiol. 264, 1993, American Physiological Society 1993, pp. R661-R667.Applicant
Nikolsky, Eugenia, M.D. et al., “Radiocontrast Nephropathy: Identifying the High-Risk Patient and the Implications of Exacerbating Renal Function,” Rev Cardiovasc Med. 2003, vol. 4, Supp. 1, © 2003 MedReviews, LLC, pp. S7-S14.Applicant
Nozawa, Takashi et al., “Effects of Long Term Renal Sympathetic Denervation on Heart Failure After Myocardial Infarction in Rats,” Sep. 22, 2001, Heart Vessels 2002, vol. 16, Springer-Verlag 2002, pp. 51-56.Applicant
Palmer, Biff F., M.D., “Managing Hyperkalemia Caused by Inhibitors of the Renin-Angiotensin-Aldosterone System,” Aug. 5, 2004, The New England Journal of Medicine 2004, vol. 351, No. 6, © 2004 Massachusetts Medical Society, pp. 585-592.Applicant
Peacock, J.M. and R. Orchardson, “Action potential conduction block of nerves in vitro by potassium citrate, potassium tartrate and potassium oxalate,” May 6, 1998, Journal of Clinical Periodontology, © 1999 Munksgaard, vol. 26, pp. 33-37.Applicant
Pettersson, A. et al., “Renal interaction between sympathetic activity and ANP in rats with chronic ischaemic heart failure,” Nov. 25, 1998, Acta Physiol. Scand. 1989, vol. 135, pp. 487-492.Applicant
Pliquett, U., “Joule heating during solid tissue electroporation,” Oct. 22, 2002, Medical & Biological Engineering and Computing 2003, vol. 41, pp. 215-219.Applicant
Podhajsky, R. J., et al. “The Histologic Effects of Pulsed and Continuous Radiofrequency Lesions at 42° C. to Rat Dorsal Root Ganglion and Sciatic Nerve,” Spine, vol. 30, No. 9, 2005, Lippincott Williams & Wilkins Inc., pp. 1008-1013.Applicant
Popovic, Jennifer .R. and Margaret J. Hall, “1999 National Hospital Discharge Survey,” Advance Data, No. 319, CDC, pp. 1-17 & 20.Applicant
Practice Guidelines Writing Committee and ESH/ESC Hypertension Guidelines Committee, “Practice Guidelines For Primary Care Physicians: 2003 ESH/ESC Hypertension Guidelines,” Published in Journal of Hypertension 2003, vol. 21, No. 10: 1011-1053, © 2003 European Society of Hypertension, pp. 1779-1786.Applicant
Pucihar, Gorazd et al., “The influence of medium conductivity on electropermeabilization and survival of cells in vitro,” May 31, 2001, Bioelectrochemistry, vol. 54, 2001, Elsevier Science B.V. 2001, pp. 107-115.Applicant
Raji, A. R. M. and R. E. M. Bowden, “Effects of High-Peak Pulsed Electromagnetic Field on the Degeneration and Regeneration of the Common Peroneal Nerve in Rats,” The Journal of Bone and Joint Surgery Aug. 1983, vol. 65-B, No. 4, © 1983 British Editorial Society of Bone and Joint Surgery, pp. 478-492.Applicant
Ram, C. Venkata S., M.D., “Understanding refractory hypertension,” May 15, 2004, Patient Care May 2004, vol. 38, pp. 12-16, 7 pages from http://www.patientcareonline.com/patcare/content/printContentPopup.jsp?id=108324.Applicant
Ravalia, A. et al., “Tachyphylaxis and epidural anesthesia,” Edgware General Hospital, Correspondence, p. 529.Applicant
Ribstein, Jean and Michael H. Humphreys, “Renal nerves and cation excretion after acute reduction in functioning renal mass in the rat,” Sep. 22, 1983, Am J Physiol, vol. 246, © 1984 the American Physiological Society, pp. F260-F265.Applicant
Richebe, Philippe, M.D. et al., “Immediate Early Genes after Pulsed Radiofrequency Treatment: Neurobiology in Need of Clinical Trials,” Oct. 13, 2004, Anesthesiology Jan. 2005, vol. 102, No. 1, © 2004 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc., pp. 1-3.Applicant
Rihal, Charanjit S. et al., “Incidence and Prognostic Importance of Acute Renal Failure After Percutaneous Coronary Intervention,” Mar. 6, 2002, Circulation May 14, 2002, vol. 10, © 2002 American Heart Association, Inc., pp. 2259-2264.Applicant
Rosen, S.M. et al., “Relationship of Vascular Reactivity to Plasma Renin Concentration in Patients with Terminal Renal Failure,” Proc. Dialysis Transplant Forum 1974, pp. 45-47.Applicant
Roth, Bradley J. and Peter J. Basser, “A Model of the Stimulation of a Nerve Fiber by Electromagnetic Induction,” IEEE Transactions on Biomedical Engineering, vol. 37, No. 6, Jun. 1990, pp. 588-597.Applicant
Rudin, Asa, M.D. et al., “Postoperative Epidural or Intravenous Analgesia after Major Abdominal or Thoraco-Abdominal Surgery,” The Journal of the American Society of Anesthesiologists, Inc., Anesthesiology 2001, vol. 95, A-970, 1 page.Applicant
Rudnick, Michael R. et al., “Contrast-induced nephropathy: How it develops, how to prevent it,” Cleveland Clinic Journal of Medicine Jan. 2006, vol. 73, No. 1, pp. 75-87.Applicant
Rump, L.C., “The Role of Sympathetic Nervous Activity in Chronic Renal Failure,” J Clinical Basic Cardiology 2001, vol. 4, pp. 179-182.Applicant
Ruohonen, Jarmo et al., “Modeling Peripheral Nerve Stimulation Using Magnetic Fields,” Journal of the Peripheral Nervous System 1997, vol. 2, No. 1, © 1997 Woodland Publications, pp. 17-29.Applicant
Scheiner, Avram, Ph.D., “The design, development and implementation of electrodes used for functional electrical stimulation,” Thesis paper, Case Western Reserve University, May 1992, 220 pages.Applicant
Schoenbach, Karl H. et al., “Intracellular Effect of Ultrashort Electrical Pulses,” Dec. 26, 2000, Bioelectromagnetics 2001, vol. 22, © 2001 Wiley-Liss Inc., pp. 440-448.Applicant
Schrier, Robert et al., “Cardiac and Renal Effects of Standard Versus Rigorous Blood Pressure Control in Autosomal-Dominant Polycystic Kidney Disease,” Mar. 23, 2002, Journal of the American Society of Nephrology, © 2002 American Society of Nephrology, pp. 1733-1739.Applicant
Scremin, Oscar U., M.D., Ph.D. and Danel P. Holschneider, M.D., “31. & 32. An Implantable Bolus Infusion Pump for the Neurosciences,” FRP, Apr. 2005, 3 pages.Applicant
Shu-Qing, Liu et al., “Old spinal cord injury treated by pulsed electric stimulation,” General Hospital of Beijing Command, Beijing, 5 pages (full article in Chinese; abstract on last page).Applicant
Shupak, Naomi M., “Therapeutic Uses of Pulsed Magnetic-Field Exposure: A Review,” Radio Science Bulletin Dec. 2003, No. 307, pp. 9-32.Applicant
Simpson, B. et al, “Implantable Spinal Infusion Devices for Chronic Pain and Spasticity: An Accelerated Systematic Review,” ASERNIP-S Report No. 42, May 2003, 56 pages.Applicant
Sisken, B.F. et al., “229.17 Influence of Non-Thermal Pulsed Radiofrequency Fields (PRF) on Neurite Outgrowth,” Society for Neuroscience, vol. 21, 1995, 2 pages.Applicant
Skeie, B. et al., “Effect of chronic bupivacaine infusion on seizure threshold to bupivacaine,” Dec. 28, 1986, Acta Anaesthesiol. Scand. 1987, vol. 31, pp. 423-425.Applicant
Skopec, M., “A Primer on Medical Device Interactions with Magnetic Resonance Imaging Systems,” Feb. 4, 1997, CDRH Magnetic Resonance Working Group, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health, Updated May 23, 1997, 17 pages, http://www.fde.gov/cdrh/ode/primerf6.html, (last accessed Jan. 23, 2006.Applicant
Slappendel, Robert et al., “The efficacy of radiofrequency lesioning of the cervical spinal dorsal root ganglion in a double blinded randomized study,” Jun. 26, 1997, Pain, vol. 73, © 1997 International Association of the Study of Pain, Elsevier Science B.V., pp. 159-163.Applicant
Sluijter, M.D., Ph.D., “Pulsed Radiofrequency,” May 17, 2005, Anesthesiology Dec. 2005, vol. 103, No. 6, © 2005 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc., pp. 1313-1314.Applicant
Sluijter, M.D., Ph.D., “Radiofrequency Part 1: The Lumbosacral Region,” Chapter 1 Mechanisms of Chronic Pain and part of Chapter 2 Spinal Pain, © 2001 FlivoPress SA, Meggen (LU), Switzerland, pp. 1-26.Applicant
Sluijter, M.D., Ph.D., “Radiofrequency Part 2: Thoracic and Cervical Region, Headache and Facial Pain,” various pages from, FlivoPress SA, Meggen (LU), Switzerland, 13 pages.Applicant
Sluijter, M.D., Ph.D., “The Role of Radiofrequency in Failed Back Surgery Patients,” Current Review of Pain 2000, vol. 4, © 2000 by Current Science Inc., pp. 49-53.Applicant
Souza, D.R.B. et al., “Chronic experimental myocardial infarction produces antinatriuresis by a renal nerve-dependent mechanism,” Oct. 14, 2003, Brazilian Journal of Medical and Biological Research 2004, vol. 37, pp. 285-293.Applicant
Standl, Thomas, M.D., et al, “Patient-controlled epidural analgesia reduces analgesic requirements compared to continuous epidural infusion after major abdominal surgery,” Aug. 29, 2002, Canada Journal of Anesthesia 2003, vol. 50, No. 3, pp. 258-264.Applicant
Stone, Gregg W., M.D. et al., “Fenoldopam Mesylate for the Prevention of Contrast-Induced Nephropathy,” JAMA Nov. 5, 2003, vol. 290, No. 17, © 2003 American Medical Association, pp. 2284-2291.Applicant
Sung, Duk Hyun, M.D. et al., “Phenol Block of Peripheral Nerve Conduction: Titrating for Optimum Effect,” Jun. 27, 2000, Arch. Phys. Med. Rehabil., vol. 82, May 2001, pp. 671-676.Applicant
Taler, Sandra J. et al., “Resistant Hypertension, Comparing Hemodynamic Management to Specialist Care,” Mar. 12, 2002, Hypertension 2002, vol. 39, 2002 American Heart Association, Inc., pp. 982-988.Applicant
Tay, Victoria KM et al., “Computed tomography fluoroscopy-guided chemical lumbar sympathectomy: Simple, safe and effective,” Oct. 31, 2001, Diagnositc Radiology, Australasian Radiology 2002, vol. 46, pp. 163-166.Applicant
Thompson, Gregory W. et al, “Bradycardia Induced by Intravascular Versus Direct Stimulation of the Vagus Nerve,” Aug. 24, 1997, The Society of Thoracic Surgeons 1998, pp. 637-642.Applicant
Thrasher, Terry N., “Unloading arterial baroreceptors causes neurogenic hypertension,” Dec. 4, 2001, Am J Physiol Regulatory Integrative Comp. Physiol., vol. 282, © 2002 the American Physiological Society, pp. R1044-R1053.Applicant
Tokuno, Hajime A. et al., “Local anesthetic effects of cocaethylene and isopropylcocaine on rat peripheral nerves,” Oct. 7, 2003, Brain Research 996, 2004, © Elsevier B.V., pp. 159-167.Applicant
Trapani, Angelo J. et al., “Neurohumoral interactions in conscious dehydrated rabbit,” Am J Physiol 1988, vol. 254, © 1988 the American Physiological Society, pp. R338-R347.Applicant
Trock, David H. et al., “The Effect of Pulsed Electromagnetic Fields in the Treatment of Osteoarthritis of the Knee and Cervical Spine. Report of Randomized, Double Blind, Placebo Controlled Trials,” Mar. 22, 1994, The Journal of Rheumatology 1994, vol. 21, pp. 1903-1911.Applicant
Troiano, Gregory C. et al., “The Reduction in Electroporation Voltages by the Addition of a Surfactant to Planar Lipid Bilayers,” May 12, 1998, Biophysical Journal, vol. 75, Aug. 1998, © the Biophysical Society, pp. 880-888.Applicant
Trumble, Dennis R., and James A. Magovern, “Comparison of Dog and Pig Models for Testing Substernal Cardiac Compression Devices,” Nov. 2003, ASAIO Journal 2004, pp. 188-192.Applicant
Tsai, E., “Intrathecal drug delivery for pain indications, technique, results,” Pain Lecture presentation, Jun. 8, 2001, 31 pages.Applicant
Uematsu, Toshihiko, M.D., Ph.D., F.I.C.A. et al., “Extrinsic Innervation of the Canine Superior Vena Cava, Pulmonary, Portal and Renal Veins,” Angiology-Journal of Vascular Diseases, Aug. 1984, pp. 486-493.Applicant
United States Renal Data System, “USRDS 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States,” National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2003, 593 pages.Applicant
Upadhyay, Pramod, “Electroporation of the skin to deliver antigen by using a piezo ceramic gas igniter,” Jan. 27, 2001, International Journal of Pharmaceutics, vol. 217, © 2001 Elsevier Science B.V., pp. 249-253.Applicant
Valente, John F. et al., “Laparoscopic renal denervation for intractable ADPKD-related pain,” Aug. 24, 2000, Nephrology Dialysis Transplantation 2001, vol. 16, European Renal Association-European Dialysis and Transplant Association, p. 160.Applicant
Van Antwerp, Bill and Poonam Gulati., “Protein Delivery from Mechanical Devices Challenges and Opportunities,” Medtronic Presentation, 19 pages.Applicant
Velazquez, Eric J., “An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry,” Aug. 5, 2004, European Heart Journal, vol. 25, © 2004 Elsevier Ltd., pp. 1911-1919.Applicant
Velez-Roa, Sonia, M.D., et al., “Peripheral Sympathetic Control During Dobutamine Infusion: Effects of Aging and Heart Failure,” Jul. 7, 2003, Journal of the American College of Cardiology 2003, vol. 42, No. 9, © 2003 American College of Cardiology Foundation, pp. 1605-1610.Applicant
Vigilance, Deon W. et al., “A Novel Approach to Increase Total Urine Output in Acute Heart Failure: Unilateral Renal nerve Blockade,” RNB Abstract AHA, 2 pages.Applicant
Villarreal, Daniel et al., “Effects of renal denervation on postprandial sodium excretion in experimental heart failure,” Oct. 29, 1993, Am J Physiol 266, 1994, pp. R1599-R1604.Applicant
Villarreal, Daniel et al., “Neurohumoral modulators and sodium balance in experimental heart failure,” Nov. 6, 1992, Am J Physiol, vol. 264, 1993, pp. H1187-H1193.Applicant
Wagner, C.D. et al, “Very low frequency oscillations in arterial blood pressure after autonomic blockade in conscious dogs,” Feb. 5, 1997, Am J Physiol Regul Integr Comp Physiol 1997, vol. 272, © 1997 the American Physiological Society, pp. 2034-2039.Applicant
Wald, Jan D. Ph.D. et al., “Cardiology Update 2003,” Sep. 11, 2003, © 2003 AG Edwards, 120 pages.Applicant
Wang, Xi et al., “Alterations of adenylyl cyclase and G proteins in aortocaval shut-induced heart failure,” Jul. 2004, Am J Physiol Heart Circ Physiol., vol. 287, © 2004 the American Physiological Society, pp. H118-H125.Applicant
Weaver, James C., “Chapter 1: Electroporation Theory, Concepts and Mechanisms,” Methods in Molecular Biology, vol. 55, Plant Cell Electroporation and Electrofusion Protocols, Edited by J.A. Nickoloff, © Humana Press Inc., pp. 3-28.Applicant
Weaver, James C., “Electroporation: A General Phenomenon for Manipulating Cells and Tissues,” Oct. 22, 1992, Journal of Cellular Biochemistry, vol. 51, © 1993 Wiley-Liss, Inc., pp. 426-435.Applicant
Weiner, Richard L., M.D., “Peripheral nerve neurostimulation,” Neurosurgery Clinics of North America 2003, vol. 14, © 2003 Elsevier Inc., pp. 401-408.Applicant
Weisbord, Steven D., M.D. and Paul M. Palevsky, M.D., “Radiocontrast-Induced Acute Renal Failure,” Jul. 10, 2004, Journal of Intensive Care Medicine 2005, vol. 20 (2), © 2005 Sage Publications, pp. 63-75.Applicant
Wilson, D.H. et al., “The Effects of Pulsed Electromagnetic Energy on Peripheral Nerve Regeneration,” Annals New York Academy of Sciences, pp. 575-585.Applicant
Wolinsky, Harvey, M.D., Ph.D. and Swan N. Thung, M.D., “Use of a Perforated Balloon Catheter to Deliver Concentrated Heparin Into the Wall of the Normal Canine Artery,” Aug. 30, 1989, JACC 1990, vol. 15, © 1990 The American College of Cardiology, pp. 475-481.Applicant
Wyss, J.Michael et al., “Neuronal control of the kidney: Contribution to hypertension,” Apr. 8, 1991, Can. J. Physiol. Pharmacol., vol. 70, 1992, pp. 759-770.Applicant
Yamaguchi, Jun-ichi et al., “Prognostic Significance of Serum Creatinine Concentration for In-Hospital Mortality in Patients With Acute Myocardial Infarction Who Underwent Successful Primary Percutaneous Coronary Intervention (from the Heart Institute of Japan Acute Myocardial Infarction [HIJAMI] Registry),” Feb. 24, 2004, The American Journal of Cardiology, vol. 93, Jun. 15, 2004, © 2004 by Excerpta Medica, Inc., pp. 1526-1528.Applicant
Ye, Richard D., M.D., Ph.D., “Pharmacology of the Peripheral Nervous System,” E-425 MSB, 6 pages.Applicant
Ye, Shaohua et al., “Renal Injury Caused By Intrarenal Injection of Phenol Increases Afferent and Efferent Renal Sympathetic Nerve Activity,” Mar. 12, 2002, American Journal of Hypertension Aug. 2002, vol. 15, No. 8, © 2002 the American Journal of Hypertension, Ltd. Published by Elsevier Science Inc., pp. 717-724.Applicant
Yong-Quan, Dong et al., “The therapeutic effect of pulsed electric field on experimental spinal cord injury,” Beijing Army General Hospital of People's Liberation Army, Beijing, 5 pages (full article in Chinese; abstract on last page).Applicant
Young, James B., M.D., FACC, “Management of Chronic Heart Failure: What Do Recent Clinical Trials Teach Us?” Reviews in Cardiovascular Medicine 2004, vol. 5, Suppl. 1, © 2004 MedReviews, LLC, pp. S3-S9.Applicant
Zanchetti, A. et al., “Neural Control of the Kidney—Are There Reno-Renal Reflexes?” Clin. and Exper. Hyper. Theory and Practice, A6 (1&2), © 1984 Marcel Dekker Inc., pp. 275-286.Applicant
Zimmermann, Ulrich, “Electrical Breakdown, Electropermeabilization and Electrofusion,” Rev. Physiol. Biochem. Pharmacol., vol. 105, © Springer-Verlag 1986, pp. 175-256.Applicant
Zucker, Irving H. et al., “The origin of sympathetic outflow in heart failure: the roles of angiotensin II and nitric oxide,” Progress in Biophysics & Molecular Biology 2004, vol. 84, © 2003 Elsevier Ltd., pp. 217-232.Applicant
Zundert, Jan Van, M.D. Fipp and Alex Cahana, M.D. Daapm, “Pulsed Radiofrequency in Chronic Pain Management: Looking for the Best Use of Electrical Current,” Pain Practice 2005, vol. 5, Issue 2, © 2005 World Institute of Pain, pp. 74-76.Applicant
Cameron, Tracy. “Micromodular Implants to Provide Electrical Stimulation of Paralyzed Muslces and Limbs.” IEEE Transactions on Biomedical Engineering, vol. 44, No. 9, Sep. 1997. pp. 781-790.Applicant
Guimaraes, Sarfim. “Vascular Adrenoceptors: An Update” pp. 319-356.Applicant
Hammer, Leah W. “Differential Inhibition of Functional Dilation of Small Arterioles by Indomethacin and Glibenclamide.” Hypertension. Feb. 2001 Part II. pp. 599-603.Applicant
Hortobagyi, Gabriel N. “Randomized Trial of High-Dose Chemotherapy and Blood Cell Autografts for High-Risk Primary Breast Carcinoma” Journal of the National Cancer Institute, vol. 92, No. 3, Feb. 2, 2000 pp. 225-233.Applicant
Janda, J., “Impact of the electrical stimulation apparatus rebox on the course of ischemic renal damage in rats,” British Library-“The world's knowledge” pp. 252-254 (translated and untranslated versions).Applicant
U.S. Appl. No. 60/236,420, Harrison et al.Applicant
U.S. Appl. No. 60/370,190.Applicant
U.S. Appl. No. 60/408,665.Applicant
U.S. Appl. No. 60/415,575.Applicant
U.S. Appl. No. 60/442,970.Applicant
“Atrial Fibrillation” Heart and Vascular Health on Yahoo! Health. 2 pages <URL: http://health.yahoo.com/topic/heart/overview/article/healthwise/hw160872;—ylt=AiBT43Ey74HQ 7ft3jAb4C.sPu7cF>.Applicant
“Heart Arrhythmia” Heart and Vascular Health on Yahoo! Health. 13 pages <URL: http://health.yahoo.com/topic/heart/overview/article/mayoclinic/21BBE2B0-128D-4AA2-A5CE215065586678;—ylt=Aqd9M5rNyHD0sbPOmHXFhLcPu7cF>.Applicant
“Isovue: Data Sheet”. Regional Health Limited. 8 pages. Mar. 11, 2003.Applicant
“Micro ETS Hyperhidrosis USA” Hyperhidrosis USA. 2 pages. <URL: http://www.hyperhidrosis-usa.com/Index.html>.Applicant
Amersham Health. “Hypague-Cysto” 6 pages. 2003.Applicant
Arentz, Thomas et al. “Incidence of pulmonary vein stenosis 2 years after radiofrequency catheter ablation of refractory atrial fibrillation.” European Heart Journal. 2003. 24; pp. 963-969.Applicant
Boehmer, John P. “Resynchronization Therapy for Chronic CHF: Indications, Devices and Outcomes”. Penn State College of Medicine: Penn State Heart and Vascular Institute. Transcatheter Cardiovascular Therapeutics 2005. 31 slides.Applicant
Bourge, Robert C. “Heart Failure Monitoring Devices: Rationale and Status” 28 pages.Applicant
Burkhoff, Daniel. “Interventional Device-Based Therapy For CHF Will Redefine Current Treatment Paradigms”. Columbia University. 2004. 32 slides.Applicant
Canbaz, Suat et al. “Electrophysiological evaluation of phrenic nerve injury during cardiac surgery—a prospective, controlled clinical study.” BioMed Central. 5 pages. 2004.Applicant
Carson, Peter. “Device-based Treatment For Chronic Heart Failure: Electrical Modulation of Myocardial Contractility”. Transcatheter Cardiovascular Therapeutics 2005. 21 slides.Applicant
Chiou, CW et al. “Efferent Vagal Innervation of the Canine Atria and Sinus and Atrioventricular Nodes”. Circulation. Jun. 1997. 95(11):2573-2584. Abstract only. 2 pages.Applicant
Cryovascular Systems, Inc. “Pre-Clinical Testing Establishing Parameters”. PowerPoint Presentation. 18 slides.Applicant
Daniel, Alan and Honig, Carl R. “Does Histamine Influence Vasodilation Caused by Prolonged Arterial Occlusion or Heavy Exercise?” The Journal of Pharmacology and Experimental Therapeutics. vol. 215 No. 2. Aug. 21, 1980. pp. 533-538.Applicant
Dong, Jun et al. “Incidence and Predictors of Pulmonary Vein Stenosis Following Catheter Ablation of Atrial Fibrillation Using the Anatomic Pulmonary Vein Ablation Approach: Results from Paired Magnetic Resonance Imaging.” Journal of Cardiovascular Electrophysiology. vol. 16, No. 8, Aug. 2005. pp. 845-852.Applicant
Fava, M. “Clinical Testing Establishing Safety & Efficacy”. PowerPoint Presentation. Cryovascular Systems, Inc. 14 slides.Applicant
Fava, M. et al. “Initial Human Experience with CryoPlasty™ in the Treatment of Infrainguinal Arterial Disease.” Abstract. 1 page.Applicant
Fischell, Tim A. et al. “Ultrasonic Energy: Effects on Valcular Function and Integrity,” Circulation: Journal of the American Heart Association. 1991. 84;pp. 1783-1795.Applicant
Hodgkin, Douglas D. et al. “Electrophysiologic Characteristics of a Pulsed Iontophoretic Drug-Delivery System in Coronary Arteries.” Journal of Cardiovascular Pharmacology. 29(1):pp. 39-44, Jan. 1997. Abstract. 2 pages.Applicant
International Search Report, PCT/US04/38498, Mailed Feb. 18, 2005, Applicant: G & L Consulting, LLC (3 pages).Applicant
Jia, Jianping and Pollock, Martin. “The pathogenesis of non-freezing cold nerve injury: Observations in the rat.” Brain. 120; pp. 631-646. 1997.Applicant
Jia, Jianping et al. “Cold injury to nerves is not due to ischaemia alone.” Brain. 121;pp. 989-1001. 1998.Applicant
Jin, Yuanzhe. et al. “Pulmonary Vein Stenosis and Remodeling After Electrical Isolation for Treatment of Atrial Fibrillation: Short- and Medium-Term Follow-Up,” PACE, vol. 27. pp. 1362-1370. Oct. 2004.Applicant
Joye, James D. and Tatsutani, Kristine. “In Vitro Studies of Arterial Freezing Injury”. 4 pages.Applicant
Joye, James D. and Tatsutani, Kristine. “In Vivo Study of Endovascular Cryotherapy for the Prevention of Restenosis.” 4 pages.Applicant
Knot, Harm J. and Nelson, Mark T. “Regulation of arterial diameter and wall [Ca2+] in cerebral arteries of rat by membrane potential and intravascular pressure.” The Journal of Physiology. 1998. 508; pp. 199-209.Applicant
Kok, Lai Chow et al. “Effect of Heating on Pulmonary Veins: How to Avoid Pulmonary Vein Stenosis.” Journal of Cardiovascular Electrophysiology. vol. 14, No. 3, Mar. 2003. pp. 250-254.Applicant
Lee, Michael A. (editor). SPORTSMed. Connecticut State Medical Society Committee on the Medical Aspects of Sports. Fall/Winter 2005. 10 pages.Applicant
Mathur, Vandana S. “Intra-Renal Drug Delivery for Fluid Overload”. FlowMedica. Transcatheter Cardiovascular Therapeutics 2005. 31 slides.Applicant
Mehran, Roxana. “Renal insufficiency and contrast nephropathy: The most common, least understood risk factor”. Cardiovascular Research Foundation. Columbia University Medical Center. 2005. 86 slides.Applicant
Packer, Douglas L. et al. “Clinical Presentation, Investigation, and Management of Pulmonary Vein Stenosis Complicating Ablation for Atrial Fibrillation.” Circulation: Journal of the American Heart Association. Feb. 8, 2005. pp. 546-554.Applicant
Pappone, Carlo and Santinelli, Vincenzo. [2005][P2-70] Safety Report of Circumferential Pulmonary Vein Ablation. A 9-Year Single-Center Experience on 6,442 Patients with Atrial Fibrillation. Abstract only. 1 page.Applicant
Pappone, Carlo et al. “[2004][759] Pulmonary Vein Denervation Benefits Paroxysmal Atrial Fibrillation Patients after Circumferential Ablation.” Abstract only. 1 page.Applicant
Purerfellner, Helmut and Martinek, Martin. “Pulmonary vein stenosis following catheter ablation of atrial fibrillation,” Current Opinion in Cardiology, 20; pp. 484-490. 2005.Applicant
Purerfellner, Helmut et al. “Pulmonary Vein Stenosis by Ostial Irrigated-Tip Ablation: Incidence, Time Course, and Prediction.” Journal of Cardiovascular Electrophysiology. vol. 14, No. 2, Feb. 2003. pp. 158-164.Applicant
Saad, Eduardo B. et al. “Pulmonary Vein Stenosis After Radiofrequency Ablation of Atrial Fibrillation: Functional Characterization, Evolution, and Influence of the Ablation Strategy.” Circulation. 108; pp. 3102-3107. 2003.Applicant
Sabbah, Hani N. “Animal Models for Heart Failure and Device Development”. Henry Ford Health System. 24 slides.Applicant
Schauerte, P et al. “Catheter ablation of cardiac autonomic nerves for prevention of vagal atrial fibrillation.” Circulation. 102(22). Nov. 28, 2000. Abstract only. 2 pages.Applicant
Schauerte, P et al. “Focal atrial fibrillation: experimental evidence for a pathophysiologic role of the autonomic nervous system.” Journal of Cardiovascular Electrophysiology. 12(5). May 2001. Abstract only. 2 pages.Applicant
Schauerte, P. et al. “Transvenous parasympathetic nerve stimulation in the inferior vena cava and atrioventricular conduction.” Journal of Cardiovascular Electrophysiology. 11(1). Jan. 2000. Abstract only. 2 pages.Applicant
Scherlag, BJ and Po, S. “The intrinsic cardiac nervous system and atrial fibrillation.” Current Opinion in Cardiology. 21(1):51-54, Jan. 2006. Abstract only. 2 pages.Applicant
Schmitt, Joseph et al. “Intravascular Optical Coherence Tomography—Opening a Window into Coronary Artery Disease”. LightLab Imaging, Inc. Business Briefing: European Cardiology 2005.Applicant
Serrador, Jorge M. “Autonomic Regulation of the Cardiovascular System”. MIT Lecture. 8 pages, 48 slides.Applicant
Siegel, RJ et al. “Clinical demonstration that catheter-delivered ultrasound energy reverses arterial vasoconstriction.” Journal of the American College of Cardiology. 1992. 20; 732-735. Summary only. 2 pages.Applicant
Sobotka, Paul A. “Treatment Strategies for Fluid Overload, CHF Patients”. CHF Solutions. Transcatheter Cardiovascular Therapeutics 2005. 20 slides.Applicant
Steffen, W. et al. “Catheter-delivered high intensity, low frequency ultrasound induces vasodilation in vivo.” European Heart Journal. 1994. 15;pp. 369-376.Applicant
Steg, PG et al. “Pulsed ultraviolet laser irradiation produces endothelium-independent relaxation of vascular smooth muscle”. Circulation: Journal of the American Heart Association. 1989. pp. 189-197.Applicant
Taka, Tomomi et al. “Impaired Flow-Mediated Vasodilation in vivo and Reduced Shear-Induced Platelet Reactivity in vitro in Response to Nitric Oxide in Prothrombotic, Stroke-Prone Spontaneously Hypertensive Rats”. Pathophysiology of Haemostasis and Thrombosis. Dec. 23, 2002. pp. 184-189.Applicant
Tamborero, David et al. “Incidence of Pulmonary Vein Stenosis in Patients Submitted to Atrial Fibrillation Ablation: A Comparison of the Selective Segmental Ostial Ablation vs. the Circumferential Pulmonary Veins Ablation.” Journal of Intervocational Cardiac Electrophysiology. 14; pp. 41-25. 2005.Applicant
Terashima, Mitsuyasu et al. “Feasibility and Safety of a Novel CryoPlasty™ System”. Poster. 1 page.Applicant
Thomas, John R. and Oakley, E. Howard N. “Chapter 15: Nonfreezing Cold Injury” Medical Aspects of Harsh Environments, vol. 1. pp. 467-490.Applicant
Vince, D. Geoffrey. “Virtual Histology: A new technique for the assessment of plaque composition”. The Cleveland Clinic Foundation. 28 pages.Applicant
Yu, Wen-Chung et al. “Acquired Pulmonary Vein Stenosis after Radiofrequency Catheter Ablation of Paroxysmal Atrial Fibrillation.” Journal of Cardiovascular Electrophysiology. vol. 12, No. 8. Aug. 2001. pp. 887-892.Applicant

Abstract